GTG Labs (GENE) - סך כל נכסי החברה
The price action for Genetic Technologies (GENE) shown below on the GURU.Markets platform records total assets at 7.01. Genetic Technologies is currently suffering from a lack of stable cash flows, as cancer screenings are only beginning to generate profit. To accelerate report delivery, the business utilizes third-party IT solutions and external contractors for sample collection. The company plans to grow its market share by implementing the geneType system in private clinics.
פילוחים אנליטיים של חברת Genetic Technologies
The efficiency of the Genetic Technologies (GENE) logistics chain for the prompt delivery of tests to laboratories depends directly on the resource base, which is reflected in the total asset valuation. This indicator, reverse-calculated via ROA, aggregates equity and liabilities, allowing investors to track the actual scale of the business and identify risks of corporate over-leverage in a timely manner.